lalotasate

Lalotasate is a novel taxane derivative developed by Shanxi Zhendong Pharmaceutical for the treatment of advanced solid tumors. It is specifically formulated as a lipid microsphere injection, a drug delivery system designed to improve the solubility and stability of the taxane moiety while potentially reducing the systemic toxicities and hypersensitivity reactions often associated with traditional solvent-based taxane formulations (such as those containing Cremophor EL). Mechanistically, lalotasate acts as a microtubule stabilizer; it binds to the beta-subunit of tubulin, promoting microtubule assembly and inhibiting depolymerization. This stabilization leads to cell cycle arrest, particularly in the G2/M phase, and ultimately triggers apoptosis in rapidly proliferating cancer cells. Lalotasate has been evaluated in Phase 1 clinical trials in China to determine its safety, tolerability, and maximum tolerated dose in patients with advanced malignancies who have failed standard therapies.

Other names

lalotasate lipid microsphere injection